EOLSEvolus, Inc.
$7.79+24% 1Y
$7.79
$3.9452 weeks$9.30
What is the market doing?
Mixed
1 neutral, 2 without dataRangebound. That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.
TrendRangeboundderived · Oct 8, 2026
Choppy, but holding above its 200-day average. Price is +26% vs its 200-day average.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How EOLS is trading
Evolus, Inc. is +24% over the past year while the S&P 500 is +18%: 6.2 points ahead of the market.
+24%
1-year return · S&P 500 +18%
- vs 200-day average
- +26%
vs 200-day average · a clear uptrend
- RSI (14)
- 49
RSI (14) · neutral
- Below its 52-week high
- 16%
Below its 52-week high
Details›
- Last close2026-10-08
- $7.79
- 1 monthS&P 500 +1.6%
- −9.1%
- 1 yearS&P 500 +18%
- +24%
- 5 yearsS&P 500 +86%
- +2.2%
- vs 50-day average$7.97
- −2.3%
- 52-week high
- $9.29
- 52-week low
- $3.94
- Annualised volatility
- 67%
| Year | Return |
|---|---|
| 2026 (year to date) | +17% |
| 2025 | −40% |
| 2024 | +4.8% |
| 2023 | +40% |
| 2022 | +15% |
| 2021 | +94% |
| 2020 | −72% |
| 2019 | +2.3% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 8 | 6 of 8 | +24% |
| Feb | 8 | 5 of 8 | +19% |
| Mar | 9 | 2 of 9 | −11% |
| Apr | 9 | 4 of 9 | −3.6% |
| May | 9 | 7 of 9 | +30% |
| Jun | 9 | 6 of 9 | +1.6% |
| Jul | 9 | 4 of 9 | −2.4% |
| Aug | 9 | 4 of 9 | +9.9% |
| Sep | 9 | 2 of 9 | −13% |
| Oct | 9 | 5 of 9 | −5.0% |
| Nov | 8 | 4 of 8 | −1.7% |
| Dec | 8 | 3 of 8 | −4.7% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
Ranks #35 of 41 by RyuScore